The company said it will address the concerns raised by the watchdog and the news will not impact its revenue.
Representative Image
Drug manufacturer Lupin informed bourses that it has received a warning letter from the US Food and Drug Administration (FDA) after an inspection of their facility in Maharashtra’s Tarapur.
The company said it will address the concerns raised by USFDA and the news will not impact its revenue.
The stock opened at Rs 674 on the BSE and is currently trading at Rs 661.50. It closed at Rs 670 yesterday.
`); } if (res.stay_updated) { $ (“.stay-updated-ajax”).html(res.stay_updated); } } catch (error) { console.log(‘Error in video’, error); } } }) }, 8000); })
